Generated: May 30, 2017
|Title:||Compounds modulating c-kit and c-fms activity and uses therefor|
|Abstract:||Compounds active on the receptor protein tyrosine kinases c-kit and c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or condition and c-fms-mediated diseases or condition, and methods for the use thereof.|
|Inventor(s):||Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Oakland, CA), Ibrahim; Prabha N. (Mountain View, CA), Hurt; Clarence R. (San Ramon, CA), Zuckerman; Rebecca (Alameda, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Emeryville, CA), Spevak; Wayne (Berkeley, CA), Wu; Guoxian (Palo Alto, CA), Zhu; Hongyao (Berkeley, CA)|
|Assignee:||Plexxikon, Inc. (Berkeley, CA)|
|Filing Date:||May 16, 2006|
|Claims:||1. A compound having the chemical structure ##STR00223## all salts, tautomers, and stereoisomers thereof, wherein: X.sub.1 is CR.sup.2, X.sub.2 is CR.sup.6, Y.sub.1 is CR.sup.4, and Y.sub.2 is CR.sup.5; L.sup.1 is --CH.sub.2--; L.sup.2 is selected from the group consisting of --O--CH.sub.2--, --NH--CH.sub.2, --NH--CH(CH.sub.3)--, and --NH--C(O); R.sup.1 is cycloalkyl or phenyl, wherein phenyl is substituted with a substituent selected from the group consisting of fluoro, chloro, methyl, methoxy and trifluoromethyl; R.sup.2 and R.sup.6 are hydrogen; one of R.sup.4 and R.sup.5 is selected from the group consisting of fluoro, chloro, bromo, lower alkyl optionally substituted with one or more fluoro, lower alkenyl, lower alkynyl, cycloalkyl, --CN, and lower alkoxy optionally substituted with one or more fluoro, lower alkoxy, di-alkylamino or cycloalkylamino, and the other of R.sup.4 and R.sup.5 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, lower alkyl optionally substituted with one or more fluoro, lower alkenyl, lower alkynyl, cycloalkyl, --CN, and lower alkoxy optionally substituted with one or more fluoro, lower alkoxy, dialkylamino, or cycloalkylamino; Ar.sub.1 is a 6 membered optionally substituted heteroarylene having the structure ##STR00224## wherein ##STR00225## indicates the point of attachment of L.sup.1 and ##STR00226## indicates the point of attachment of L.sup.2, and wherein the indicated N is either .dbd.N-- or --N.dbd.; n is 1; F and J are both C; P is CR and Q is CH, wherein R is hydrogen, methyl or methoxy; T is CH. |
2. The compound according to claim 1, wherein Y.sub.1 is CH and Y.sub.2 is CR.sup.5.
3. The compound according to claim 2, wherein R.sup.5 is fluoro, chloro, lower alkyl or lower alkoxy.
4. The compound according to claim 2, wherein R.sup.5 is chloro or methoxy.
5. The compound according to claim 1, wherein Y.sub.2 is CH and Y.sub.1 is CR.sup.4.
6. The compound according to claim 5, wherein R.sup.4 is fluoro, chloro, lower alkyl or lower alkoxy.
7. The compound according to claim 5, wherein R.sup.4 is chloro or methoxy.
8. A composition comprising: a pharmaceutically acceptable carrier; and a compound according to claim 1.
9. A kit comprising a composition according to claim 8.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.